M42
Mubadala Tower, Abu Dhabi, 4200, United Arab Emirates
Overview
M42 is a provider of healthcare services with a focus on technology that is at the cutting edge of medical advancement.M42 integrates medical and data-centric technologies with facilities to provide the most precise, patient-centric, and preventative treatment. It is created with the alliance of Mubadala and G42. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 combines G42 Healthcare’s unique medical and data-centric technologies with Mubadala Health’s world-class patient services and state-of-the-art facilities to provide the highest level of personalized, precise, and preventative care.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Health Care
- Medical
Investment portfolio
- Juvenescence
Led · Series B · May 2025
Juvenescence is a clinical-stage, AI-enabled biotech focused on developing novel medicines to extend healthy lifespan. Its approach centers on developing therapies that target core ageing mechanisms to treat and prevent age-related diseases. The company’s diverse pipeline includes clinical and near-clinical candidates addressing cognition, cardio-metabolism, immunity and cellular repair. Juvenescence also holds investments in a number of companies and platform technologies focused on AI and regenerative medicine. Led by CEO Dr Richard Marshall and founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan, the company is based in Ramsey, UK. In May 2025 it closed a $76M first tranche of a Series B-1 to advance its therapeutics into clinical development and enhance its core medicine pipeline.
Team
No current team members are available.